Document is current
Any future updates will be listed below
-
Authors
Mrózek, Krzysztof https://orcid.org/0000-0002-1408-5063
Kohlschmidt, Jessica
Blachly, James S. https://orcid.org/0000-0002-4275-5562
Nicolet, Deedra
Carroll, Andrew J. https://orcid.org/0000-0001-9844-730X
Archer, Kellie J. https://orcid.org/0000-0003-1555-5781
Mims, Alice S. https://orcid.org/0000-0002-8971-2199
Larkin, Karilyn T.
Orwick, Shelley https://orcid.org/0000-0002-4537-1409
Oakes, Christopher C.
Kolitz, Jonathan E.
Powell, Bayard L.
Blum, William G.
Marcucci, Guido https://orcid.org/0000-0002-3983-5908
Baer, Maria R.
Uy, Geoffrey L. https://orcid.org/0000-0002-7809-0996
Stock, Wendy https://orcid.org/0000-0002-8349-9200
Byrd, John C.
Eisfeld, Ann-Kathrin https://orcid.org/0000-0001-6442-1419
- License Information
-
More Information
Article History
Received: 23 January 2023
Revised: 3 February 2023
Accepted: 8 February 2023
First Online: 23 February 2023
Competing interests
: JSB is a consultant for and reported honoraria from KITE, INNATE, AstraZeneca and AbbVie. ASM received research funding from Leukemia and Lymphoma Society’s Beat AML clinical study, Aptevo, Daiichi Sankyo, Glycomemetics, Kartos Pharmaceuticals, Xencor and Genentech; and is a consultant for Aptevo, Abbvie, BMS, Glycomemetics, Jazz Pharmaceuticals, Kura Oncology, and Syndax Pharmaceuticals. BLP is a consultant for Cornerstone Pharmaceuticals and reported research funding from Ambit Biosciences, Cornerstone, Genentech, Hoffman LaRoche, Jazz Pharmaceuticals, Novartis and Pfizer. WGB reported honoraria from Abbvie, Syndax, and AmerisourceBergen and research funding from Celyad Oncology, Nkarta, Xencor, Forma Therapeutics and Leukemia and Lymphoma Society. GLU is a consultant for AbbVie, Agios, Jazz, GlaxoSmithKline, Genentech, and Novartis; reported honoraria from Astellas and research funding from Macrogenics. JCB consults for Astellas, AstraZeneca, Novartis, Pharmacyclics, Syndax and Trillium; receives honoraria from Astellas, AstraZeneca, Novartis, Pharmacyclics, Syndax and Trillium; he is a Chairman of the Scientific Advisory Board of Vincerx Pharmaceuticals and a member of advisory committee of Newave; and is a current equity holder of Vincerx Pharmaceuticals. A-KE is the spouse of Christopher J. Walker who is currently employed by Karyopharm Therapeutics. The remaining authors declare no competing financial interests.
